Implantation of Cartilage Mini-grafts Made From Donor Cells to Treat Chondral Lesions of the Knee
Implantation of Allogenic Cartilage Mini-grafts: First-In-Human Study for Treating Chondral Lesions of the Knee. Open Cohort, Small Sample Size With 6 Months Follow-Up
The purpose of this study is to investigate the safety and feasibility of implanting allogeneic cartilage mini-grafts (or allogenic Cartibeads) into cartilage defects in the knee.
Allogeneic Cartibeads are engineered from allogeneic articular chondrocytes (from a donor's cartilage cells). The donor, who in 2022 participated in the Autologous Cartibeads clinical trial (Swissmedic ID 701146), consented to use his leftover cells for production of mini-grafts for other patients in this study. Our patented, standardized methodology allows production of bead-shaped mini-grafts (Allogeneic Cartibeads). These grafts are 1 to 2 mm in diameter and have similar characteristics to native hyaline cartilage.
Allogeneic Cartibeads are implanted into the patient's cartilage defect. Patients are then followed for 6 months for assessment of study endpoints, with safety being the primary outcome.
研究概览
研究类型
注册 (实际的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习地点
-
-
Canton Ticino
-
Lugano、Canton Ticino、瑞士、6962
- Ente Ospedaliero Cantonale (EOC)
-
-
Canton of Geneva
-
Geneva、Canton of Geneva、瑞士、1206
- Center for Sports Medicine and Exercise, Hirslanden Clinique La Colline
-
Geneva、Canton of Geneva、瑞士、1211
- Geneva University Hospitals (HUG)
-
-
Canton of Zurich
-
Zurich、Canton of Zurich、瑞士、8008
- Balgrist University Hospital (BUH)
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Key inclusion criteria:
- Symptomatic cartilage lesion(s) of the femorotibial and/or patellofemoral compartments (includes isolated, multiple and kissing lesions)
- Cartilage lesion(s) ≥ 1 cm2 and ≤ 10 cm2
- ICRS grade 3 or 4
- Aged over 18 years
Key exclusion criteria
- Inability to undergo MRI
- Cartilage specific surgery within 6 months from baseline
- Cartilage therapeutic injection within 3 months from baseline
- Chronic inflammatory arthritis and/or infectious arthritis
学习计划
研究是如何设计的？
设计细节
- 主要用途：治疗
- 分配：不适用
- 介入模型：单组作业
- 屏蔽：无（打开标签）
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的：Allogeneic Cartibeads
Implantation of allogeneic cartilage mini-grafts (Allogeneic Cartibeads) |
Implantation of allogeneic cartilage mini-grafts (Cartibeads) by minimally invasive surgery (arthroscopy or mini arthrotomy). Cartibeads should entirely fill the defect zone, followed by a thin layer of surgical glue (TISSEEL Fibrin Sealant). |
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Safety
大体时间：From enrolment to the end of follow-up at 6 months
|
Recording, identifying, documenting and reporting all Serious Adverse Events (SAEs) and Adverse Events (AEs). |
From enrolment to the end of follow-up at 6 months
|
合作者和调查者
赞助
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他研究编号
- 701779
- 701779 (其他标识符：Swissmedic)
- 2023-02168 (其他标识符：BASEC)
- 64935 (其他标识符：HumRes)
- 000005866 (其他标识符：SNCTP)
- 2023 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)？
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.